Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally - Seite 2

In addition, new clinical and real-world evidence continues to affirm the use of Dexcom CGM is central to optimal diabetes management, while helping to expand CGM access and use in new populations. Some of the most recent evidence showcasing the effectiveness of Dexcom CGM will be highlighted in posters, presentations and during the Dexcom Symposia at ATTD.

Dexcom Symposia Overview

Dexcom Continues to Lead in CGM Technology Across the Diabetes Spectrum
Thursday, February 23, 2023, 3:00 – 4:30 PM CET, in Plenary Hall A6
Moderated by Daniel Chernavvsky, MD

• This education program will focus on Dexcom CGM and its use with both Type 1 and Type 2 diabetes patients. Real world experience and correlational outcomes of Dexcom G7 and its unique features will be shared, as well as an introduction to the new 2GO-CGM study, focusing on the use of Dexcom CGM use in Type 2, intensive and non-intensive insulin treated patients. Finally, the next generation Dexcom-TypeZero AID algorithm and first in-human study results will be presented.

Dexcom CGM: Transforming the Course of Care for Type 2 Diabetes
Friday, February 24, 2023, 8:00 – 8:50 AM CET, in Hall A3
Moderated by Noriko Kodani, MD, PhD

• This program reviews recently updated clinical practice guidelines on rtCGM use in Type 2 diabetes management. There will be a presentation highlighting new data on the use of rtCGM early in the course of care for Type 2 diabetes. Additionally, there will be an examination on how improving access for people with Type 2 diabetes, on less intensive insulin regimens are positioned to impact utilization and adoption of rtCGM in clinical practice. Finally, there will be a review of ways to simplify the review of CGM data, specifically for Type 2 diabetes, and steps that have been taken to integrate Dexcom Clarity data into electronic health records for more efficient clinical workflows.

Ahead of the Curve: Inpatient Use of Dexcom G6 and Automated Insulin Delivery Systems
Friday, February 24, 2023, 4:40 – 6:00 PM CET, in Hall A5
Moderated by Erin Cobry, MD

• The emergence of diabetes technology in the hospital holds the potential to revolutionize glycemic management and change the standard of care. In this session, participants will learn how these technologies are fueling the possibility in different patient populations and hospital settings. The esteemed panel will discuss continuation of Dexcom rtCGM upon hospital admission and an associated accuracy analysis in the pediatric population, preservation of intensive care unit capacity by using Dexcom G6 in a stepdown unit for patients admitted with diabetic ketoacidosis, feasibility of an automated insulin delivery system in patients with Type 1 or Type 2 diabetes in a medical-surgical unit, and perioperative use of fully closed-loop insulin delivery.

For more information about these presentations and to register to virtually attend the conference, visit https://attd.kenes.com/.